More Articles

Biotech firms try to limit biosimilar substitution in US Biosimilars/News | Posted 08/02/2013

FDA is still to approve a biosimilar and has yet to issue final guidelines outlining the regulatory requirements for approval of a biosimilar in the US.

Conflict-of-interest policies reduce brand-name prescribing Generics/Research | Posted 08/02/2013

Psychiatrists who are exposed to conflict-of-interest (COI) policies during their residency are less likely to prescribe brand-name antidepressants after graduation than those who train in residenc...

Assessment of biosimilarity under the BPCI Act Biosimilars/Research | Posted 08/02/2013

The Biologics Price Competition and Innovation (BPCI) Act defines a biosimilar as a product that is highly similar to the reference product notwithstanding minor differences in clinically inactive...

Generic Doxil approval may help alleviate drug shortages Pharma News | Posted 08/02/2013

FDA announced on 4 February 2013 that the agency had approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).

Prescribing in Scotland increases but drug costs drop Reports | Posted 08/02/2013

Spending on medicine in Scotland was 11% less in 2011–2012 compared to spending in 2004–2005. This is despite the volume of prescriptions increasing by 33% during that time, according to a new repo...

G-CSF biosimilars – World Marrow Donor Association position Biosimilars/Research | Posted 08/02/2013

The World Marrow Donor Association (WMDA) has expressed its position on the use of granulocyte colony-stimulating factor (G-CSF) biosimilars in healthy donors in an article published in the journal...

Watson buys women’s health company Uteron Generics/News | Posted 08/02/2013

Generics giant Watson Pharmaceuticals, now known as Actavis, announced on 23 January 2013 that it has completed the acquisition of Belgium-based Uteron Pharma for US$150 million in cash up front, a...

Mobilization of stem cells in healthy donors by G-CSF biosimilars shows comparable efficacy and safety to Neupogen Biosimilars/Research | Posted 01/02/2013

Originator human recombinant granulocyte colony-stimulating factor (G-CSF) filgrastim has been widely used for the mobilization of CD34+ stem cells in healthy donors. However, there is limited...